Dual Pathway Inhibition for Vascular Protection in Patients with Atherosclerotic Disease: Rationale and Review of the Evidence
出版年份 2020 全文链接
标题
Dual Pathway Inhibition for Vascular Protection in Patients with Atherosclerotic Disease: Rationale and Review of the Evidence
作者
关键词
-
出版物
THROMBOSIS AND HAEMOSTASIS
Volume 120, Issue 08, Pages 1147-1158
出版商
Georg Thieme Verlag KG
发表日期
2020-06-29
DOI
10.1055/s-0040-1713376
参考文献
相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。- Dual-pathway inhibition for secondary and tertiary antithrombotic prevention in cardiovascular disease
- (2020) Davide Capodanno et al. Nature Reviews Cardiology
- Rivaroxaban Plus Aspirin Versus Aspirin in Relation to Vascular Risk in the COMPASS Trial
- (2019) Sonia S. Anand et al. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY
- Association of Multiple Enrichment Criteria With Ischemic and Bleeding Risks Among COMPASS-Eligible Patients
- (2019) Arthur Darmon et al. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY
- Estimating individual lifetime benefit and bleeding risk of adding rivaroxaban to aspirin for patients with stable cardiovascular disease: results from the COMPASS trial
- (2019) Tamar I de Vries et al. EUROPEAN HEART JOURNAL
- 2019 ESC Guidelines for the diagnosis and management of chronic coronary syndromes
- (2019) Juhani Knuuti et al. EUROPEAN HEART JOURNAL
- Association Between Low-Dose Rivaroxaban With or Without Aspirin and Ischemic Stroke Subtypes
- (2019) Kanjana S. Perera et al. JAMA Neurology
- Rivaroxaban Reduces Arterial Thrombosis by Inhibition of FXa-Driven Platelet Activation via Protease Activated Receptor-1
- (2019) Tobias Petzold et al. CIRCULATION RESEARCH
- Rationale and design for the Vascular Outcomes study of ASA along with rivaroxaban in endovascular or surgical limb revascularization for peripheral artery disease (VOYAGER PAD)
- (2018) Warren H. Capell et al. AMERICAN HEART JOURNAL
- Anti-thrombotic options for secondary prevention in patients with chronic atherosclerotic vascular disease: what does COMPASS add?
- (2018) K A A Fox et al. EUROPEAN HEART JOURNAL
- Antithrombotic Therapy for Peripheral Artery Disease
- (2018) Mohamad A. Hussain et al. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY
- Rivaroxaban with or without aspirin in patients with stable coronary artery disease: an international, randomised, double-blind, placebo-controlled trial
- (2018) Stuart J Connolly et al. LANCET
- Rivaroxaban with or without aspirin in patients with stable peripheral or carotid artery disease: an international, randomised, double-blind, placebo-controlled trial
- (2018) Sonia S Anand et al. LANCET
- D-Dimer Levels and Effect of Rivaroxaban on Those Levels and Outcomes in Patients With Acute Coronary Syndrome (An ATLAS ACS-TIMI 46 Trial Substudy)
- (2018) Fahad AlKhalfan et al. AMERICAN JOURNAL OF CARDIOLOGY
- ACC/AHA Versus ESC Guidelines on Dual Antiplatelet Therapy
- (2018) Davide Capodanno et al. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY
- 2017 ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation
- (2017) Borja Ibanez et al. EUROPEAN HEART JOURNAL
- 2017 ESC Guidelines on the Diagnosis and Treatment of Peripheral Arterial Diseases, in collaboration with the European Society for Vascular Surgery (ESVS)
- (2017) Victor Aboyans et al. EUROPEAN HEART JOURNAL
- Clinically significant bleeding with low-dose rivaroxaban versus aspirin, in addition to P2Y12 inhibition, in acute coronary syndromes (GEMINI-ACS-1): a double-blind, multicentre, randomised trial
- (2017) E Magnus Ohman et al. LANCET
- Rivaroxaban with or without Aspirin in Stable Cardiovascular Disease
- (2017) John W. Eikelboom et al. NEW ENGLAND JOURNAL OF MEDICINE
- Ticagrelor versus Clopidogrel in Symptomatic Peripheral Artery Disease
- (2017) William R. Hiatt et al. NEW ENGLAND JOURNAL OF MEDICINE
- Coronary Atherosclerotic Vulnerable Plaque: Current Perspectives
- (2017) Christodoulos Stefanadis et al. Journal of the American Heart Association
- Advances in Thrombosis and Hemostasis
- (2016) Jeffrey I. Weitz et al. CIRCULATION RESEARCH
- Evidence-Based Development and Rationale for Once-Daily Rivaroxaban Dosing Regimens Across Multiple Indications
- (2016) Dagmar Kubitza et al. CLINICAL AND APPLIED THROMBOSIS-HEMOSTASIS
- 2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS
- (2016) Paulus Kirchhof et al. EUROPACE
- Ticagrelor for Prevention of Ischemic Events After Myocardial Infarction in Patients With Peripheral Artery Disease
- (2016) Marc P. Bonaca et al. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY
- The effect of a dual or a triple antithrombotic therapy with apixaban on thrombus formation in vivo and in an ex vivo perfusion chamber model
- (2016) Stefan Weisshaar et al. MEDICINE
- Edoxaban, a direct factor Xa inhibitor, suppresses tissue-factor induced human platelet aggregation and clot-bound factor Xa in vitro: Comparison with an antithrombin-dependent factor Xa inhibitor, fondaparinux
- (2016) Yuko Honda et al. THROMBOSIS RESEARCH
- Expression of pro-inflammatory genes in human endothelial cells: Comparison of rivaroxaban and dabigatran
- (2016) Peter Ellinghaus et al. THROMBOSIS RESEARCH
- 2015 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation
- (2015) Marco Roffi et al. EUROPEAN HEART JOURNAL
- Effects of Rivaroxaban on Platelet Activation and Platelet–Coagulation Pathway Interaction
- (2015) Elisabeth Perzborn et al. JOURNAL OF CARDIOVASCULAR PHARMACOLOGY AND THERAPEUTICS
- Role of high shear rate in thrombosis
- (2015) Lauren D.C. Casa et al. JOURNAL OF VASCULAR SURGERY
- Long-Term Use of Ticagrelor in Patients with Prior Myocardial Infarction
- (2015) Marc P. Bonaca et al. NEW ENGLAND JOURNAL OF MEDICINE
- Effect of Darapladib on Major Coronary Events After an Acute Coronary Syndrome
- (2014) Michelle L. O’Donoghue et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Thrombosis formation on atherosclerotic lesions and plaque rupture
- (2014) L. Badimon et al. JOURNAL OF INTERNAL MEDICINE
- 2014 AHA/ACC Guideline for the Management of Patients With Non–ST-Elevation Acute Coronary Syndromes
- (2014) Ezra A. Amsterdam et al. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY
- Targeting Therapy to the Fibrin-Mediated Pathophysiology of Acute Coronary Syndrome
- (2013) Harvey White CLINICAL AND APPLIED THROMBOSIS-HEMOSTASIS
- 2013 ESC guidelines on the management of stable coronary artery disease
- (2013) EUROPEAN HEART JOURNAL
- The effect of food on the absorption and pharmacokinetics of rivaroxaban
- (2013) Jan Stampfuss et al. INTERNATIONAL JOURNAL OF CLINICAL PHARMACOLOGY AND THERAPEUTICS
- Reduction of Stent Thrombosis in Patients With Acute Coronary Syndromes Treated With Rivaroxaban in ATLAS-ACS 2 TIMI 51
- (2013) C. Michael Gibson et al. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY
- Effectiveness and safety of novel oral anticoagulants as compared with vitamin K antagonists in the treatment of acute symptomatic venous thromboembolism: a systematic review and meta-analysis
- (2013) T. van der Hulle et al. JOURNAL OF THROMBOSIS AND HAEMOSTASIS
- Comparison of the efficacy and safety of new oral anticoagulants with warfarin in patients with atrial fibrillation: a meta-analysis of randomised trials
- (2013) Christian T Ruff et al. LANCET
- Thrombin Generation in the Glasgow Myocardial Infarction Study
- (2013) Machiel Smid et al. PLoS One
- Open-label, randomized study of the effect of rivaroxaban with or without acetylsalicylic acid on thrombus formation in a perfusion chamber
- (2013) Michael Wolzt et al. THROMBOSIS RESEARCH
- Update on acute coronary syndromes: the pathologists' view
- (2012) Erling Falk et al. EUROPEAN HEART JOURNAL
- Effects of rivaroxaban, acetylsalicylic acid and clopidogrel as monotherapy and in combination in a porcine model of stent thrombosis
- (2012) E.M. BECKER et al. JOURNAL OF THROMBOSIS AND HAEMOSTASIS
- Vorapaxar for secondary prevention of thrombotic events for patients with previous myocardial infarction: a prespecified subgroup analysis of the TRA 2°P-TIMI 50 trial
- (2012) Benjamin M Scirica et al. LANCET
- Vorapaxar in the Secondary Prevention of Atherothrombotic Events
- (2012) David A. Morrow et al. NEW ENGLAND JOURNAL OF MEDICINE
- Dabigatran vs. placebo in patients with acute coronary syndromes on dual antiplatelet therapy: a randomized, double-blind, phase II trial
- (2011) J. Oldgren et al. EUROPEAN HEART JOURNAL
- Apixaban with Antiplatelet Therapy after Acute Coronary Syndrome
- (2011) John H. Alexander et al. NEW ENGLAND JOURNAL OF MEDICINE
- Apixaban versus Warfarin in Patients with Atrial Fibrillation
- (2011) Christopher B. Granger et al. NEW ENGLAND JOURNAL OF MEDICINE
- Rivaroxaban versus Warfarin in Nonvalvular Atrial Fibrillation
- (2011) Manesh R. Patel et al. NEW ENGLAND JOURNAL OF MEDICINE
- Rivaroxaban in Patients with a Recent Acute Coronary Syndrome
- (2011) Jessica L. Mega et al. NEW ENGLAND JOURNAL OF MEDICINE
- Thrombin-Receptor Antagonist Vorapaxar in Acute Coronary Syndromes
- (2011) Pierluigi Tricoci et al. NEW ENGLAND JOURNAL OF MEDICINE
- Rivaroxaban—Once daily, oral, direct factor Xa inhibition Compared with vitamin K antagonism for prevention of stroke and Embolism Trial in Atrial Fibrillation: Rationale and Design of the ROCKET AF study
- (2010) AMERICAN HEART JOURNAL
- Three-year follow-up and event rates in the international REduction of Atherothrombosis for Continued Health Registry
- (2009) M. J. Alberts et al. EUROPEAN HEART JOURNAL
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreDiscover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversation